Jesus Juarez Casillas,^{1,2*} Thomas A. Hope,³ Jeremie Calais,² Fei Jiang,⁴ Wolfgang P. Fendler,⁵ Abuzar Moradi Tuchayi,² Vishnu Murthy,⁶ Matthias Eiber,⁷ Ken Herrmann,⁵ Madeleine J Karpinski,⁵ Lela Theus,⁸ Andrew T. Nguyen,⁸ Luisa Willner,⁷ Türkay Hekimsoy,⁷ Ariel B. Bourla,⁹ Sharon McCarthy,⁹ Branko Milandinovic,¹⁰ Megan M Price,⁹ Alexander Kretschmer,¹¹ Jose Zamalloa¹²

¹UCLA Radiation Oncology, Los Angeles, CA, USA; ²Ahmanson Translational Theranostics Division, University of California, Los Angeles, CA, USA; ³Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA; ⁴University of California, San Francisco, CA, USA; ⁵Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany; ⁶Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA; ⁷Department of Nuclear Medicine, School of Medicine and Health, TUM University Hospital, Technical University of Munich, Munich, Germany; ⁸Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA; ⁹Johnson & Johnson, Raritan, NJ, USA; ¹⁰Johnson & Johnson, San Diego, CA, USA; ¹¹Johnson & Johnson, Neuss, Germany; ¹²Johnson & Johnson, Lawrence, NJ, USA

*Presenting author

Presented by Jesus Juarez Casillas at the 2025 American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium; February 13-15, 2025; San Francisco, CA

Click anywhere to view this interactive poster

https://www.congresshub.com/Oncology/GU2025/Apal utamide/Casillas

Copies of this presentation obtained through Quick Response (QR) Codes are for personal use only and may not be reproduced without permission from ASCO[®] or the author of this presentation.



Jesus Juarez Casillas, Thomas A. Hope, Jeremie Calais, Fei Jiang, Wolfgang P. Fendler, Abuzar Moradi Tuchayi, Vishnu Murthy, Matthias Eiber, Ken Herrmann, Madeleine J Karpinski, Lela Theus, Andrew T. Nguyen, Luisa Willner, Türkay Hekimsoy, Ariel B. Bourla, Sharon McCarthy, Branko Milandinovic, Megan M Price, Alexander Kretschmer, Jose Zamalloa

KEY TAKEAWAY



Incorporating PSMA PET-CT results at time of BCR may enable more precise and effective treatment strategies

BCR, Biochemical recurrence; PSMA PET-CT, Prostate-specific membrane antigen positron emission tomography-computed tomography.



Presented by Jesus Juarez Casillas at the 2025 American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium; February 13-15, 2025; San Francisco, CA NAVIGATION

KEY TAKEAWAY

CONCLUSIONS

INTRODUCTION

Patient characteristics

METHODS

METHODS Patient disposition RESULTS

RESULTS MFS unadjusted RESULTS MFS adjusted

APPENDIX

Jesus Juarez Casillas, Thomas A. Hope, Jeremie Calais, Fei Jiang, Wolfgang P. Fendler, Abuzar Moradi Tuchayi, Vishnu Murthy, Matthias Eiber, Ken Herrmann, Madeleine J Karpinski, Lela Theus, Andrew T. Nguyen, Luisa Willne Türkay Hekimsoy, Ariel B. Bourla, Sharon McCarthy, Branko Milandinovic, Megan M Price, Alexander Kretschmer, Jose Zamalloa

CONCLUSIONS



Patients with LAHR PCa who have PSMA PET+ lesions at BCR following RP experience an MFS period three times shorter than patients without PSMA PET+ lesions at BCR

A longer follow-up is required to better evaluate associations with overall survival in this patient population



Further analyses with a larger patient population across institutions in the United States and Europe are ongoing to increase the robustness of these MFS rate estimates

BCR, Biochemical recurrence; LAHR PCa, Locally advanced high-risk prostate cancer; MFS, Metastasis free survival; PSMA PET, Prostate-specific membrane antigen positron emission tomography; RP, Radical prostatectomy.





Presented by Jesus Juarez Casillas at the 2025 American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium; February 13-15, 2025; San Francisco, CA

$\bigcirc \bigcirc $
KEY TAKEAWAY
CONCLUSIONS
INTRODUCTION
METHODS
METHODS Patient disposition
RESULTS Patient characteristics
RESULTS MFS unadjusted
RESULTS MFS adjusted
APPENDIX

NAVIGATION

Jesus Juarez Casillas, Thomas A. Hope, Jeremie Calais, Fei Jiang, Wolfgang P. Fendler, Abuzar Moradi Tuchayi, Vishnu Murthy, Matthias Eiber, Ken Herrmann, Madeleine J Karpinski, Lela Theus, Andrew T. Nguyen, Luisa Willne Türkay Hekimsoy, Ariel B. Bourla, Sharon McCarthy, Branko Milandinovic, Megan M Price, Alexander Kretschmer, Jose Zamalloa

INTRODUCTION

- LAHR PCa comprises 10%–15% of new PCa diagnoses in the United States and carries a higher risk of BCR, reaching 60% after definitive treatment, compared to low-risk disease¹
- Conventional imaging, including CT, MRI, and single-photon bone scans, often fails to detect disease sites at lower PSA levels during BCR²
- PSMA PET-CT is used to stage PCa at BCR and has a higher sensitivity than conventional imaging (i.e. CT and bone scan)^{3,4}
- There is a significant lack of evidence on how PSMA PET findings affect treatment decisions,³ including strategies such as radiation, androgen deprivation therapy, or systemic therapies, and their timing; as well as the resulting clinical outcomes in patients with conventional imaging LAHR PCa experiencing BCR after RP
- We investigated the association between PSMA PET-CT results and MFS by conventional imaging in LAHR PCa patients with BCR who had undergone RP

1. Shore ND et al. Prostate Cancer Prostatic Dis. 2024;27(2):192-201. 2. Mena E et al. World J Urol. 2021 Mar;39(3):687-699. 3. Meijer D et al. Eur Urol Oncol. 2022;5(2):146-52. 4. Hoffman A et al. Cancers (Basel). 2023;29;15(13):3402.

BCR, Biochemical recurrence; CT, -computed tomography; LAHR, Locally advanced high-risk; MFS, Metastasis free survival; MRI, Magnetic resonance imaging; PCa, prostate cancer; PSA, Prostate-specific antigen; PSMA, Prostate-specific membrane antigen; PET, Positron emission tomography, RP, Radical prostatectomy.

Prostate Cancer



NAVIGATION
KEY TAKEAWAY
CONCLUSIONS
INTRODUCTION
METHODS
METHODS Patient disposition
RESULTS Patient characteristics
RESULTS MFS unadjusted
RESULTS MFS adjusted
APPENDIX

Jesus Juarez Casillas, Thomas A. Hope, Jeremie Calais, Fei Jiang, Wolfgang P. Fendler, Abuzar Moradi Tuchayi, Vishnu Murthy, Matthias Eiber, Ken Herrmann, Madeleine J Karpinski, Lela Theus, Andrew T. Nguyen, Luisa Willne Türkay Hekimsoy, Ariel B. Bourla, Sharon McCarthy, Branko Milandinovic, Megan M Price, Alexander Kretschmer, Jose Zamalloa

METHODS

- Patients with LAHR PCa (characterized by either PSA >20 ng/mL or Gleason Score 8–10, or tumor staging T4a or higher on initial diagnosis and no evidence of metastasis) who experienced BCR following RP and received a PSMA PET-CT scan were retrospectively identified from two academic centers in the United States between January 2016 and January 2024
- PSMA PET+ status was defined as having evidence of a distant lesion by PSMA PET
- Treatment changes were recorded from the time of BCR and up to 60 days post-BCR
- MFS was estimated by conventional imaging (CT and bone scan)
- Time-to-event analysis was performed between patients with PSMA PET positive (PSMA PET+) and PSMA PET negative (PSMA PET-) lesions to estimate effect of imaging results on MFS
- A 1:1 propensity score matching was used to control confounding factors. The propensity score is defined as the probability of being assigned to PSMA PET+ group conditioning on the PSA and treatment change at BCR. This probability is estimated by a logistic regression.


BCR, Biochemical recurrence; CT, Computed tomography; LAHR, Locally advanced high-risk; MFS, Metastasis free survival; PCa, prostate cancer; PSMA, Prostate-specific membrane antigen; PET, Positron emission tomography; PSA, Prostate specific antigen; RP, Radical prostatectomy.

Prostate Cancer



KEY TAKEAWAY
CONCLUSIONS
INTRODUCTION
METHODS
METHODS Patient disposition
RESULTS Patient characteristics
RESULTS MFS unadjusted
RESULTS MFS adjusted
APPENDIX

Jesus Juarez Casillas, Thomas A. Hope, Jeremie Calais, Fei Jiang, Wolfgang P. Fendler, Abuzar Moradi Tuchayi, Vishnu Murthy, Matthias Eiber, Ken Herrmann, Madeleine J Karpinski, Lela Theus, Andrew T. Nguyen, Luisa Willner, Türkay Hekimsoy, Ariel B. Bourla, Sharon McCarthy, Branko Milandinovic, Megan M Price, Alexander Kretschmer, Jose Zamalloa



antigen; RP, Radical prostatectomy.

Prostate Cancer



Jesus Juarez Casillas, Thomas A. Hope, Jeremie Calais, Fei Jiang, Wolfgang P. Fendler, Abuzar Moradi Tuchayi, Vishnu Murthy, Matthias Eiber, Ken Herrmann, Madeleine J Karpinski, Lela Theus, Andrew T. Nguyen, Luisa Willner, Türkay Hekimsoy, Ariel B. Bourla, Sharon McCarthy, Branko Milandinovic, Megan M Price, Alexander Kretschmer, Jose Zamalloa

RESULTS

- 433 LAHR RP patients with mCRPC who had received PSMA PET-CT at BCR were included
- Of 433 patients, 157 were PSMA PET+
- Overall median follow-up time was 47.3 months (IQR: 21.2– 72.8)

Patient characteristics				
	PSMA PET+ (n=157)	PSMA PET- (n=276)	Cohen's D	p-value
Age, mean (SD), y	63.1 (7.51)	64.3 (7.10)	0.169	0.114
Race, n (%)	(D.		0.294
White	117 (81.2%)	192 (81.0%)		
Black or African American	3 (2.1%)	12 (5.1%)		
Other	24 (16.7%)	33 (13.9%)		
ECOG status				0.544
0	95	149		
1-2	24	31		
Baseline T stage	6			0.810
T1	12	31		
T2	34	75		
ТЗ-Т4	30	59		
Gleason score ^a				0.396
3+3, 3+4	9 (6.4%)	13 (5.0%)		
4+3	7 (5.0%)	25 (9.6%)		
3+5, 4+4, 5+3	68 (48.2%)	123 (47.3%)		
4+5, 5+4, 5+5	57 (40.4%)	99 (38.1%)		
PSA at BCR, median (range)	1.35 (0.2–217.2)	0.51 (0.2–19.9)	0.332	0.013
Time to RP, median (range), mo	2.15 (0.0-45.7)	2.37 (0.0-88.9)	0.023	0.810
Imaging within 4 weeks of PSMA PET, n (%)				0.317
No imaging within 4 weeks	146 (93.0%)	258 (93.5%)		
CT, Bone scan	5 (3.2%)	13 (4.7%)		
Other	6 (3.8%)	5 (1.8%)		



APPENDIX

^aGleason score reported is the highest value between either biopsy or RP. 🔰

BCR, Biochemical recurrence; CT, Computed tomography; ECOG, Eastern Cooperative Oncology Group; IQR, interquartile range ; LA HR, Locally advanced high-risk; mCRPC, Metastatic castration-resistant prostate cancer; mo, Month; PSA, Prostate-specific antigen; PSMA, Prostate-specific membrane antigen; PET, Positron emission tomography; RP, Radical prostatectomy; SD, Standard deviation; y, year.


Prostate Cancer



Jesus Juarez Casillas, Thomas A. Hope, Jeremie Calais, Fei Jiang, Wolfgang P. Fendler, Abuzar Moradi Tuchayi, Vishnu Murthy, Matthias Eiber, Ken Herrmann, Madeleine J Karpinski, Lela Theus, Andrew T. Nguyen, Luisa Willner, Türkay Hekimsoy, Ariel B. Bourla, Sharon McCarthy, Branko Milandinovic, Megan M Price, Alexander Kretschmer, Jose Zamalloa

RESULTS

 MFS was significantly shorter for PSMA PET+ versus PSMA PET- patients by conventional imaging (p=0.006; HR: 2.39, 95% CI: 1.3-4.5)



MFS for PSMA PET+ versus PSMA PET- patients (unadjusted)

Solid lines are Kaplan-Meier estimates of survival probability. Dashed lines are associated 95% confidence intervals. CI, Confidence interval; HR, Hazard ratio; MFS, Metastasis frees urvival; PET, Positron emission tomography; PSMA, Prostate-specific membrane antigen.

NAVIGATION **KEY TAKEAWAY** CONCLUSIONS INTRODUCTION METHODS METHODS Patient disposition RESULTS Patient characteristics RESULTS MFS unadjusted RESULTS **MFS** adjusted APPENDIX

Prostate Cancer



Jesus Juarez Casillas, Thomas A. Hope, Jeremie Calais, Fei Jiang, Wolfgang P. Fendler, Abuzar Moradi Tuchayi, Vishnu Murthy, Matthias Eiber, Ken Herrmann, Madeleine J Karpinski, Lela Theus, Andrew T. Nguyen, Luisa Willner, Türkay Hekimsoy, Ariel B. Bourla, Sharon McCarthy, Branko Milandinovic, Megan M Price, Alexander Kretschmer, Jose Zamalloa

NAVIGATION RESULTS MFS for PSMA PET+ versus PSMA PET- patients The difference in MFS (adjusted for PSA and treatment change at BCR) remained significant after **KEY TAKEAWAY** PSMA PET-PSMA PET+ propensity score matching CONCLUSIONS (p=0.012; HR: 3.0, 95% CI: 1.2-100 7.5) INTRODUCTION Survival probability (%) 75 METHODS METHODS 50 Patient disposition RESULTS Patient characteristics 25 HR (95% CI): 3.0 (1.2-7.5), p=0.012 RESULTS MFS unadjusted RESULTS 0 MFS adjusted 1000 2000 3000 APPENDIX Time (days) Number at risk PSMA PET 64 34 0 111 65 PSMA PET+ 111 34 0 Solid lines are Kaplan-Meier estimates of survival probability. Dashed lines are associated 95% confidence intervals.

BCR, Biochemical recurrence; CI, Confidence interval; HR, Hazard ratio; MFS, Metastasis free survival; PET, Positron emission tomography; PSA, Prostatespecific antigen; PSMA, Prostate-specific membrane antigen.



Jesus Juarez Casillas, Thomas A. Hope, Jeremie Calais, Fei Jiang, Wolfgang P. Fendler, Abuzar Moradi Tuchayi, Vishnu Murthy, Matthias Eiber, Ken Herrmann, Madeleine J Karpinski, Lela Theus, Andrew T. Nguyen, Luisa Willner Türkay Hekimsoy, Ariel B. Bourla, Sharon McCarthy, Branko Milandinovic, Megan M Price, Alexander Kretschmer, Jose Zamalloa

APPENDIX

REFERENCES

- 1. Shore ND et al. *Prostate Cancer Prostatic Dis.* 2024;27(2):192-201.
- 2. Mena E et al. World J Urol. 2021 Mar;39(3):687-699.
- 3. Meijer D et al. Eur Urol Oncol. 2022;5(2):146-52.
- 4. Hoffman A et al. *Cancers (Basel*). 2023;29;15(13):3402.

DISCLOSURES

JJC: Received funding from the Christiaan W. Schiepers Theranostics Fellowship award.

ACKNOWLEDGMENTS:

Kalpana Tilekar, PhD (SIRO Medical Writing Pvt. Ltd., India) provided writing assistance and Jennifer Han, MS (Johnson & Johnson) provided additional editorial support. Amit Kavle (SIRO Medical Writing Pvt. Ltd., India) provided graphic designing support.

FUNDING: This study was funded by Johnson & Johnson.

Prostate (Cance
------------	-------



Presented by Jesus Juarez Casillas at the 2025 American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium; February 13-15, 2025; San Francisco, CA

NAVIGATION
KEY TAKEAWAY
CONCLUSIONS
INTRODUCTION
METHODS
METHODS Patient disposition
RESULTS Patient characteristics
RESULTS MFS unadjusted
RESULTS MFS adjusted

APPENDIX